GSK 6-K
GSK plc (GSK)
6-K
2026-09-15
For: 2026-09-15
View Original
Added on
September 15, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 15 September 2026, London UK
GSK to acquire potential best-in-class T cell-engager (TCE) for
multiple myeloma from Chimagen Biosciences
●
Trispecific
TCE targeting T cells and two tumour antigens has potential for
differentiated efficacy and safety over current TCEs
●
Programme
to enter clinic in 2027
●
Deal
aligned to GSK’s portfolio in blood cancer and approach of
acquiring differentiated assets with validated targets
GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement
to acquire a potential best-in-class trispecific T cell-engager
(TCE) from Chimagen Biosciences (Chimagen), a privately held
biotechnology company. GSK plans to develop and commercialise the
asset for multiple myeloma, with the programme expected to enter
phase I trials in 2027.
TCEs have shown transformational efficacy in multiple myeloma but
have been associated with difficult tolerability profiles. The
Chimagen trispecific asset is designed to address this by binding
to T cells while simultaneously targeting two strategically
selected and validated tumour-associated antigens. This targeted
approach aims to achieve a deeper and more durable response
compared to existing TCEs, along with an improved tolerability
profile. This could enable broader adoption and earlier use in
multiple myeloma treatment, providing an important advancement for
patients who may require multiple options depending on their
treatment needs. The US TCE market for multiple myeloma is expected
to exceed $10 billion by 2032.[1]
Hesham Abdullah, Senior Vice President, Global Head Oncology,
R&D, GSK, said: “Today’s deal secures a promising T
cell engager and advances GSK’s leadership goals in blood
cancer. The agreement complements our existing portfolio in
multiple myeloma, adding a new potential option to address the
different needs of patients facing this complex
disease.”
Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences,
said: “Our mission has
always been to translate cutting-edge innovation into life-changing
medicines. Working with GSK combines our precision T-cell engager
programme with their global development and commercial capabilities
to redefine care for multiple myeloma patients. This agreement also
marks another major milestone for our platforms as we continue to
build an industry-leading pipeline of multi-specific antibody
candidates.”
Multiple myeloma is the third most common blood cancer globally,
with approximately 180,000 new cases diagnosed globally each
year.
[2],[3]
While generally considered treatable,
it is not currently curable, and research into new therapies is
vital as the disease commonly becomes refractory to available
treatments.[4]
The agreement builds on GSK’s existing relationship with
Chimagen, following a previous agreement to acquire CMG1A46, a
clinical-stage dual CD19 and CD20-targeted TCE currently in phase I
trials for B-cell malignancies and B-cell dependent autoimmune
disorders.
Financial considerations
Under the terms of the agreement, GSK will pay an upfront fee to
acquire full global rights to the TCE programme. Chimagen will also
be eligible to receive success-based development and commercial
milestone payments. The agreement has a total potential value of up
to $750 million.
This agreement is subject to customary closing
conditions.
About Chimagen Biosciences
Chimagen Biosciences is a clinical-stage biotechnology company
focused on the discovery and development of novel multi-specific T
cell-engagers and NK cell-engagers generated by proprietary
antibody engineering platforms. Its mission is to advance
breakthrough therapies that improve the lives of patients with
cancer and autoimmune diseases. For more information, please visit
www.chimagen.com.
GSK in oncology
Our ambition in oncology is to help increase overall quality of
life, maximise survival and change the course of disease, expanding
from our current focus on blood and women’s cancers into lung
and gastrointestinal cancers, as well as other solid tumours. This
includes accelerating priority programmes such as antibody-drug
conjugates Ris Rez targeting B7-H3 and Mo-Rez targeting B7-H4, and
velzatinib, a highly selective KIT tyrosine kinase
inhibitor.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
Joanna
Tuplin
|
+44 (0)
7788 351650
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
7823 523885
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q2 Results for 2026.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
[1] External commercial
forecasts.
[2] Sung H, Ferlay J, Siegel R,
et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021;71(3):209-249.
doi:10.3322/caac.21660.
[3] Kazandjian D. Multiple
myeloma epidemiology and survival: A unique malignancy. Semin
Oncol. 2016;43(6):676–681.doi:
10.1053/j.seminoncol.2016.11.004.
[4] Global Cancer Observatory.
International Agency for Research on Cancer. World Health
Organization. Multiple Myeloma fact sheet. Available at:
https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf.
Accessed 5 March 2025.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
15, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|